TAE684 (NVP-TAE684)

For research use only. Not for use in humans.

目录号:S1108

TAE684 (NVP-TAE684) Chemical Structure

CAS No. 761439-42-3

TAE684 (NVP-TAE684) 是一种有效的,选择性 ALK 抑制剂,在无细胞试验中 IC50 为3 nM,作用于ALK比作用于InsR选择性高100倍。TAE684 (NVP-TAE684) 可诱导细胞周期阻滞和凋亡。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 2201.25 现货
RMB 1308.07 现货
RMB 2379.43 现货
RMB 6308.29 现货
RMB 15315.3 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的TAE684 (NVP-TAE684)发表文献67篇:

产品安全说明书

ALK抑制剂选择性比较

生物活性

产品描述 TAE684 (NVP-TAE684) 是一种有效的,选择性 ALK 抑制剂,在无细胞试验中 IC50 为3 nM,作用于ALK比作用于InsR选择性高100倍。TAE684 (NVP-TAE684) 可诱导细胞周期阻滞和凋亡。
特性 NVP-TAE684 作为治疗难治愈和复发的ALK阳性淋巴癌的一种策略,但是还没进行临床实验。
靶点
ALK [1]
(Cell-free assay)
3 nM
体外研究

NVP-TAE684选择性有效抑制ALK激酶,作用于其他激酶则没有明显的交叉反应。NVP-TAE684 有效抑制Ba/F3 NPM-ALK 细胞增殖,IC50 为3 nM, 1 μM NVP-TAE684对Ba/F3 细胞存活没有效果。NVP-TAE684 也抑制表达NPM-ALK人类ALCL细胞系的增殖,包括Karpas-299和SU-DHL-1,IC50为2-5 nM。分子模型显示L258 可能为NVP-TAE684的主要激酶选择性影响因素之一。用NVP-TAE684处理,快速且持久地抑制NPM-ALK的磷酸化作用。NVP-TAE684 作用于表达NPM-ALK的 Ba/F3 细胞和ALCL病患细胞系,诱导细胞凋亡,且使细胞周期停在G1期。[1] NVP-TAE684 作用于H3122 CR细胞,显著克服细胞抗Crizotinib的特性, 含有融合致癌基因EML4-ALK, 降低细胞生长,抑制ALK磷酸化作用和诱导细胞凋亡。[2] 30 nM NVP-TAE684可抑制mALK R1279Q 突变表达诱导的神经突增生。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 MlvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTrWoU6UUN3ME2wMlAxODB4MEOg{txO NEG0T2pUSU6JRWK=
SF539 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInqSFhKSzVyPUCuNFAxPTZ2IN88US=> NETzXVJUSU6JRWK=
DEL NXPUbpVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHzTWM2OD1yLkCwNFkzPyEQvF2= M2nSdnNCVkeHUh?=
NB1 MnmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHuZ2ZKSzVyPUCuNFAyPjJizszN MVLTRW5ITVJ?
SR MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTTcYF3UUN3ME2wMlAxOjd5IN88US=> NIrqbJlUSU6JRWK=
KARPAS-299 NHTpV29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTGXlVYUUN3ME2wMlAzOzh2IN88US=> NX:5Ulh5W0GQR1XS
MHH-CALL-2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\sXYJKSzVyPUCuNFI6PTJizszN NYjnUZZHW0GQR1XS
SU-DHL-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXrfZB3UUN3ME2wMlA1QDZ3IN88US=> NWfncpI5W0GQR1XS
A4-Fuk NX3USm5oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2no[WlEPTB;MD6wOVU3PSEQvF2= MlnoV2FPT0WU
EW-1 Moi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwMUCyOVYh|ryP MUTTRW5ITVJ?
NOS-1 NXXiZmdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2W1[2lEPTB;MD6xNFI6PCEQvF2= MkOzV2FPT0WU
EW-16 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nteGlEPTB;MD6xNFU3QCEQvF2= NGDYdYpUSU6JRWK=
TE-11 M{DZ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTBwMU[wPVYh|ryP MlLRV2FPT0WU
SW982 NWTvcWdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLUTWM2OD1yLkG2OFc5KM7:TR?= NV\ibGNMW0GQR1XS
LAN-6 NVvZdlBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4S5dGlEPTB;MD6xO|Q1OyEQvF2= MoXUV2FPT0WU
MZ1-PC NYXqRXdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwMUe4N|Uh|ryP NEPyfGlUSU6JRWK=
KS-1 NYLLd5hlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3v5[2lEPTB;MD6xPVM1OyEQvF2= M4LXWXNCVkeHUh?=
PSN1 NEfrbWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDte4lKSzVyPUCuNVk3OzFizszN NEWwXGpUSU6JRWK=
LC-2-ad MnHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInqSFhKSzVyPUCuNVk3QTJizszN NInyR5pUSU6JRWK=
COLO-320-HSR NHn2dYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{H4UmlEPTB;MD6xPVc4PiEQvF2= NYLZb3pSW0GQR1XS
OPM-2 MoS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHWOWdKSzVyPUCuNlI3PjlizszN MnrCV2FPT0WU
SK-NEP-1 M2T5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHXSmdKSzVyPUCuNlM2OjRizszN M{DWeXNCVkeHUh?=
ALL-PO M3HsXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHP1eZdKSzVyPUCuNlQ2OjRizszN NXnmN2t5W0GQR1XS
CMK MkXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jTTWlEPTB;MD6yOVU{KM7:TR?= Moi5V2FPT0WU
NCI-H1648 NF61ZndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEO1N4VKSzVyPUCuNlc5PTVizszN NHrObG5USU6JRWK=
SIG-M5 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGqwN25KSzVyPUCuNlkyPTlizszN NEez[mZUSU6JRWK=
TGBC24TKB MnHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDiSHJWUUN3ME2wMlMxOjF6IN88US=> MkWzV2FPT0WU
DOHH-2 NYLtbY9JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwM{GyNFQh|ryP MXvTRW5ITVJ?
NB69 NXz3dZhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnPdmhKSzVyPUCuN|E4QDdizszN M3;tN3NCVkeHUh?=
MFH-ino MmXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXmPWpHUUN3ME2wMlMzPTJ|IN88US=> NVzPbFQyW0GQR1XS
KP-N-RT-BM-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPmTWM2OD1yLkOzNVI{KM7:TR?= NXu4b4R1W0GQR1XS
MONO-MAC-6 NVzBRVVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzwe3FKSzVyPUCuN|MzQTFizszN NUOwcYtuW0GQR1XS
ATN-1 M1rYZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jObWlEPTB;MD6zN|MxOyEQvF2= MVLTRW5ITVJ?
NTERA-S-cl-D1 M1PsXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXKTWM2OD1yLkOzN|k3KM7:TR?= NFfxNoNUSU6JRWK=
L-540 NGXabppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PqZWlEPTB;MD6zOlk5QCEQvF2= MlzhV2FPT0WU
GB-1 NV7hXVdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDITWM2OD1yLkO4PFY4KM7:TR?= MUHTRW5ITVJ?
MV-4-11 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTZdXo4UUN3ME2wMlM6PDR4IN88US=> NH3qW4NUSU6JRWK=
KG-1 M1PPdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULiTIdMUUN3ME2wMlM6PTZzIN88US=> NFPUemZUSU6JRWK=
OVCAR-4 M2D6bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DOUGlEPTB;MD60NFU3QSEQvF2= M2jzPXNCVkeHUh?=
NEC8 M4PLTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\zSnRKSzVyPUCuOFEzQTJizszN Ml\DV2FPT0WU
SK-MM-2 M2r0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33YPWlEPTB;MD60NVYxQSEQvF2= M4XWZ3NCVkeHUh?=
TE-8 Mnn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTBwNEK4PEDPxE1? M1LDRXNCVkeHUh?=
697 NXnnRo9vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nhT2lEPTB;MD60N|IyPSEQvF2= MnjHV2FPT0WU
NB14 M1XTUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVThV4sxUUN3ME2wMlQ{QDJ4IN88US=> NVfOdnpmW0GQR1XS
GDM-1 MlHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrmS3hpUUN3ME2wMlQ4OTF4IN88US=> NXPZNpd1W0GQR1XS
HUTU-80 NHTZXXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvjWYRKSzVyPUCuOFc{PzVizszN M4n3cnNCVkeHUh?=
HL-60 MmnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XVPGlEPTB;MD60PFE1OiEQvF2= NE\6SYVUSU6JRWK=
OCI-AML2 M13nUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXL5cVFTUUN3ME2wMlQ5OzJ6IN88US=> M1zIO3NCVkeHUh?=
ML-2 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[4TWM2OD1yLkS5NFMyKM7:TR?= M4DE[nNCVkeHUh?=
ES4 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTBwNEmxNFkh|ryP MXPTRW5ITVJ?
NCI-H747 MkPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULC[|Q4UUN3ME2wMlQ6QDlizszN MXnTRW5ITVJ?
RL95-2 M4XvRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvyW4ZKSzVyPUCuOVAyOTJizszN NUftU3VsW0GQR1XS
TE-15 NFPme3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnL0TWM2OD1yLkWxNVI1KM7:TR?= NHn0bolUSU6JRWK=
TE-12 NWfOcXF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFG2OYVKSzVyPUCuOVM{PDlizszN MknYV2FPT0WU
LB1047-RCC MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHsPZBXUUN3ME2wMlU1PTR7IN88US=> NGPa[mRUSU6JRWK=
LB831-BLC MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MomwTWM2OD1yLkW1NFI{KM7:TR?= MYrTRW5ITVJ?
NCI-H1355 MofoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NICxSFdKSzVyPUCuOVUyQDRizszN NWW4T4VEW0GQR1XS
CTV-1 NYfseJZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPieFJrUUN3ME2wMlU2PjJ2IN88US=> NWrwZ3NsW0GQR1XS
RXF393 M1\iWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXiTWM2OD1yLkW1O|k1KM7:TR?= MVzTRW5ITVJ?
SW872 NVzLTFlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwNU[3NlQh|ryP MmTrV2FPT0WU
MPP-89 M3LYOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmn4TWM2OD1yLkW3PFg1KM7:TR?= NXGyW3M3W0GQR1XS
RPMI-8226 NWW0OWJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITVTnlKSzVyPUCuOlM2OjZizszN NITiVGlUSU6JRWK=
LS-1034 Mn3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkC4TWM2OD1yLk[zOVgh|ryP MnjpV2FPT0WU
SJSA-1 M{\Y[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTzOFZLUUN3ME2wMlY{PzJ3IN88US=> NUTvWHV6W0GQR1XS
HOP-62 NHi5S29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlm0TWM2OD1yLk[1NFM{KM7:TR?= NWezU2RtW0GQR1XS
KGN NYj4e2ZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGe2[4xKSzVyPUCuOlYyPjhizszN MVrTRW5ITVJ?
D-336MG M1\VVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLwTo9KSzVyPUCuOlYyPjlizszN MWDTRW5ITVJ?
LS-411N MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTBwNke0OlIh|ryP M1vicXNCVkeHUh?=
TE-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrvbo9KSzVyPUCuOlkxPzRizszN NX;GcnpiW0GQR1XS
LB996-RCC M13vZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTBwNkmzPFkh|ryP NIDaUoNUSU6JRWK=
TE-10 MoPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnFTWM2OD1yLkexOFk3KM7:TR?= MVzTRW5ITVJ?
NCI-SNU-16 NGPWb29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTiTWM2OD1yLkeyOlY1KM7:TR?= MmrVV2FPT0WU
ES8 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPFe2JKSzVyPUCuO|Q6PzVizszN MXXTRW5ITVJ?
COLO-800 NWflRmlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDKWmdKSzVyPUCuO|Y3QTVizszN M2HhRnNCVkeHUh?=
ES6 NX3hTYtIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPUUo9KSzVyPUCuO|c2PTlizszN MWTTRW5ITVJ?
L-363 MmPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTyTWM2OD1yLkiyN|c2KM7:TR?= NGnDVGJUSU6JRWK=
NMC-G1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV[4e|d6UUN3ME2wMlg{OjN|IN88US=> MmftV2FPT0WU
LU-134-A M2HkSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXWeIliUUN3ME2wMlg{QTF{IN88US=> M4P2[nNCVkeHUh?=
SF268 MnP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jOd2lEPTB;MD64OFA1OiEQvF2= NUDXWVR[W0GQR1XS
KARPAS-45 NGfTPZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fPcWlEPTB;MD64OFI3OyEQvF2= M4DDZ3NCVkeHUh?=
TGW NGXnS3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPWTWM2OD1yLki1PFY{KM7:TR?= MX7TRW5ITVJ?
CHP-126 MlX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXJV4FKSzVyPUCuPFU6PTdizszN NIT1b2lUSU6JRWK=
MOLT-16 Mmf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1z5[2lEPTB;MD64O|U5QSEQvF2= NFO2WWRUSU6JRWK=
LB771-HNC M2mzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXpTWM2OD1yLki5O|U4KM7:TR?= MY\TRW5ITVJ?
NALM-6 NIqxRZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PrcGlEPTB;MD65NFc{QSEQvF2= NVe1bJk3W0GQR1XS
GCIY M{myTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\CTWM2OD1yLkm1OVI3KM7:TR?= NYezNGZNW0GQR1XS
IST-MES1 NWjNS2prT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXMTWM2OD1yLkm4PFI1KM7:TR?= NYH4cpU5W0GQR1XS
LB2241-RCC MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrtTWM2OD1yLkm4PFQh|ryP MWHTRW5ITVJ?
BL-70 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXn1T2ZpUUN3ME2wMlk6PTN3IN88US=> MY\TRW5ITVJ?
NB17 M1jqbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnxUo5KSzVyPUGuNFA3OzlizszN MVXTRW5ITVJ?
LXF-289 NILSTWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILUUXNKSzVyPUGuNFMxPzZizszN MVrTRW5ITVJ?
TK10 NITvSY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvyTWM2OD1zLkC1NFY{KM7:TR?= M3v3e3NCVkeHUh?=
K5 NHjKWYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTYU4k4UUN3ME2xMlA3Ojd2IN88US=> M3\CdXNCVkeHUh?=
NCI-H716 MnHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13PV2lEPTB;MT6wO|I2QSEQvF2= MVLTRW5ITVJ?
HCE-T NFHJNGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrLTWM2OD1zLkC4PFE6KM7:TR?= NWWwd5FVW0GQR1XS
GI-1 NEXPR|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;KTWM2OD1zLkC5O|k5KM7:TR?= M{TXU3NCVkeHUh?=
KARPAS-422 NYTHSpNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33rfGlEPTB;MT6xNFAzOiEQvF2= MkPLV2FPT0WU
TE-9 NH;lbJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHPR|g6UUN3ME2xMlEyOzJ6IN88US=> MWfTRW5ITVJ?
SF126 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDMTWM2OD1zLkGxOVY5KM7:TR?= NIP3VHdUSU6JRWK=
BB30-HNC NVnDWIVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTFwMUOxNVIh|ryP NUj0U|dmW0GQR1XS
NCI-H1304 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[xemdKSzVyPUGuNVM{OzhizszN M1j4NXNCVkeHUh?=
HEL MoPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjhSWlKSzVyPUGuNVQ5QTVizszN MVPTRW5ITVJ?
HAL-01 NHzzTJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGSxWItKSzVyPUGuNVUzQDNizszN NVTMV3UzW0GQR1XS
SK-LMS-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PFbGlEPTB;MT6xOVk4PCEQvF2= MUfTRW5ITVJ?
SW954 NXfqSlBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Xh[WlEPTB;MT6xPVU3PyEQvF2= NV;KPZF{W0GQR1XS
D-283MED MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfWbnhoUUN3ME2xMlIzOzd7IN88US=> MnfOV2FPT0WU
NCI-H1882 NWXFXpdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\zVJp4UUN3ME2xMlI{QDlizszN MW\TRW5ITVJ?
GI-ME-N MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETDU25KSzVyPUGuNlUzODhizszN M3jadnNCVkeHUh?=
SK-PN-DW M33sW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLpTWM2OD1zLkK2N|Q5KM7:TR?= NIL5dpVUSU6JRWK=
C2BBe1 MoXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIf5XYdKSzVyPUGuNlkyOTdizszN NV;FRZBoW0GQR1XS
A704 M1zVWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;hTWM2OD1zLkOyOlg6KM7:TR?= NYjHUm1vW0GQR1XS
KALS-1 NV;H[m9GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGftWVlKSzVyPUGuN|QxQCEQvF2= M1HGWXNCVkeHUh?=
ETK-1 M4XDWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPxTWM2OD1zLkO0OFg6KM7:TR?= NWSzVYFEW0GQR1XS
LB647-SCLC MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTFwM{S5PFYh|ryP NVvRN3BuW0GQR1XS
OCUB-M NHPnVYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTFwM{[xOFMh|ryP NEPoO3VUSU6JRWK=
NCI-H720 MkfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrNeY1IUUN3ME2xMlM3Ozd6IN88US=> M4LJSHNCVkeHUh?=
NB13 M1rNUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjRTWM2OD1zLkO3Nlk{KM7:TR?= M{fDW3NCVkeHUh?=
GR-ST Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTFwM{i3OVch|ryP M2fhZ3NCVkeHUh?=
DU-4475 M2D4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrIbYE{UUN3ME2xMlQ2QDV|IN88US=> NHy5cG1USU6JRWK=
HCC2157 M4\QWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7q[29FUUN3ME2xMlQ3PjV7IN88US=> MYDTRW5ITVJ?
RKO NYPkU|FyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTFwNEm5NlIh|ryP Mo\rV2FPT0WU
LS-123 NUXDXlZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTFwNUG1PVQh|ryP MkSxV2FPT0WU
NCI-H69 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXKOJFKSzVyPUGuOVU5OTFizszN M1fPdHNCVkeHUh?=
SW962 NWLudWZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3e3R2lEPTB;MT61OlE{KM7:TR?= Mmj0V2FPT0WU
PF-382 NGr4OXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PhXmlEPTB;MT61Olk3KM7:TR?= M2XqXHNCVkeHUh?=
A101D MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3OyNWlEPTB;MT61O|EyOyEQvF2= NXvCNY9OW0GQR1XS
NB10 NYezOY9oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\nNI1XUUN3ME2xMlU4Ozl{IN88US=> MUXTRW5ITVJ?
NB5 M1PIfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTFwNUi0O|Yh|ryP NE\XbIpUSU6JRWK=
HCE-4 MnL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUe3PHZ6UUN3ME2xMlYxQDVizszN NFi5T4tUSU6JRWK=
HT-144 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHRSpZuUUN3ME2xMlY{OTlizszN NGfzSm1USU6JRWK=
NCI-H524 M1\DXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjh[3hKSzVyPUGuOlQ{ODdizszN MVvTRW5ITVJ?
NKM-1 MorXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLGTWM2OD1zLk[4OlYh|ryP M1q3eXNCVkeHUh?=
KURAMOCHI Mnz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrOVWpCUUN3ME2xMlY6PTd|IN88US=> M{niT3NCVkeHUh?=
NCI-H187 NVnoOJFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTLTWM2OD1zLkewNFM3KM7:TR?= NGHLXVVUSU6JRWK=
U-266 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWn3T3pKUUN3ME2xMlc{QDR{IN88US=> MkL5V2FPT0WU
BL-41 MoDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rkOWlEPTB;MT63OlI4OiEQvF2= NV[3ZZBWW0GQR1XS
SK-N-DZ M2e2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTFwN{izNFkh|ryP NV6xPXpiW0GQR1XS
Daudi NYjK[plJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrKTWM2OD1zLke4PVY4KM7:TR?= Ml65V2FPT0WU
CPC-N Mn\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;2bmtnUUN3ME2xMlg2ODl4IN88US=> MXzTRW5ITVJ?
EM-2 MkPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTFwOEWxJO69VQ>? M3PWOnNCVkeHUh?=
HCC1187 M2Tn[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{L3NGlEPTB;MT64OlI1OSEQvF2= M{nQXHNCVkeHUh?=
LP-1 MlfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnkXphKSzVyPUGuPFcyPDNizszN MXnTRW5ITVJ?
CAS-1 MmHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjOTWM2OD1zLkm4Nlk6KM7:TR?= MUTTRW5ITVJ?
NB7 NFvIflFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nIV2lEPTB;Mj6wNFU2PSEQvF2= NVnRNXp2W0GQR1XS
VA-ES-BJ NIH0NWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXOOpU2UUN3ME2yMlAyPTF|IN88US=> MoLaV2FPT0WU
SNU-C2B Mn3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:4XGdlUUN3ME2yMlA{OzVzIN88US=> MVPTRW5ITVJ?
LOXIMVI NEW2UGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjDSnZ4UUN3ME2yMlA3Pzh4IN88US=> Mo\jV2FPT0WU
NCI-H1581 NX\Xe4lvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDUSGRKSzVyPUKuNVE2PTlizszN M2\mRXNCVkeHUh?=
IST-SL2 M3Lzcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3xflQxUUN3ME2yMlEzPDR3IN88US=> MXLTRW5ITVJ?
NOMO-1 NXO4OnN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\mTWM2OD1{LkG3Olg{KM7:TR?= MXXTRW5ITVJ?
TE-6 M2fD[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\IW2lEPTB;Mj6xPVA2KM7:TR?= MYPTRW5ITVJ?
NCI-H526 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrHZop[UUN3ME2yMlE6OTRzIN88US=> NFznW5VUSU6JRWK=
MSTO-211H MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTJwMkCwOFEh|ryP MXnTRW5ITVJ?
LS-513 NV;WXGZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4j5bWlEPTB;Mj6yNlI3QSEQvF2= NXvwO5VoW0GQR1XS
NCI-SNU-1 MlTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIC3SHdKSzVyPUKuN|MzPTZizszN M4\uOnNCVkeHUh?=
BB65-RCC NYrMVG1UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3VTWM2OD1{LkO3OFk{KM7:TR?= M3W3cHNCVkeHUh?=
GT3TKB NGLWNolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkC3TWM2OD1{LkO5PVczKM7:TR?= NUjmWFBrW0GQR1XS
OS-RC-2 NHTLPXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfPTWM2OD1{LkSyN|QyKM7:TR?= MVzTRW5ITVJ?
NCI-H2126 NG\4cFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIK3N3FKSzVyPUKuOFM3PzRizszN NXTuRXZkW0GQR1XS
SK-UT-1 M{OyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTJwNEe0Olch|ryP MXXTRW5ITVJ?
DMS-114 MknWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPNPYpKSzVyPUKuOlE2OjRizszN NYfVOYxHW0GQR1XS
ONS-76 NYfST3dTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHMU4pKSzVyPUKuOlM3PDFizszN NV3BToVRW0GQR1XS
8-MG-BA MlW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3zWGFKSzVyPUKuOlU1OTRizszN NH\0NGtUSU6JRWK=
BOKU MnTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXZTWM2OD1{LkeyO|Y1KM7:TR?= MorpV2FPT0WU
LAMA-84 NVHuTndYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;pfHlKSzVyPUKuO|k6OTJizszN MV7TRW5ITVJ?
ES1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnu2TWM2OD1{LkixPFA1KM7:TR?= NV7sO3Q3W0GQR1XS
NCI-H1395 NHnBcWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\BSWJPUUN3ME2yMlgzODF{IN88US=> MVTTRW5ITVJ?
A388 NX63WG5QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml6wTWM2OD1{Lkm2NVch|ryP M4K4bnNCVkeHUh?=
NCCIT M4S5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofHTWM2OD1|LkC4PFYzKM7:TR?= NXK2WFhFW0GQR1XS
HD-MY-Z NXL3c2poT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrQOJdrUUN3ME2zMlE{OjB|IN88US=> Mn7nV2FPT0WU
NCI-H510A NGfRZWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojGTWM2OD1|LkG4PVQ{KM7:TR?= MmexV2FPT0WU
NCI-N87 MkiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTNwMkCwNkDPxE1? NWnDeZh6W0GQR1XS
SCLC-21H NVvRepB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Cx[2lEPTB;Mz6yOlg2QSEQvF2= NYXnXINuW0GQR1XS
SH-4 NYnGboZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DoemlEPTB;Mz6yPFc6PyEQvF2= NXn2[XFYW0GQR1XS
QIMR-WIL NXrCWW1zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvNPW5MUUN3ME2zMlMzQDR7IN88US=> M4XuOnNCVkeHUh?=
KM12 Ml;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkf6TWM2OD1|LkOzOVQ1KM7:TR?= NGm5bohUSU6JRWK=
ST486 MnjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rn[GlEPTB;Mz61N|g5OyEQvF2= MlvhV2FPT0WU
HC-1 M3Xhd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTNwNkKwNlgh|ryP M1XIRXNCVkeHUh?=
BV-173 M{LZWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvmd41MUUN3ME2zMlY1ODh6IN88US=> NVPwcFZDW0GQR1XS
EW-24 NX60VmFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jyd2lEPTB;Mz62OlQ{PCEQvF2= M1PRUXNCVkeHUh?=
LU-65 NEm3RpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknlTWM2OD1|Lk[4O|Eh|ryP MlnOV2FPT0WU
ECC4 NEi5fmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTaTWM2OD1|Lke3OVYh|ryP MXPTRW5ITVJ?
ARH-77 NFfPTIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIq4XnZKSzVyPUSuNVExPjdizszN M2HVdnNCVkeHUh?=
BC-3 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTXZ5VKSzVyPUSuNVMxPjhizszN M17xc3NCVkeHUh?=
SNB75 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTRwMk[xPUDPxE1? NGrEZ3JUSU6JRWK=
MEG-01 Mn3LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTRwMke0NVkh|ryP MXXTRW5ITVJ?
NCI-H1417 NH;0SW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTRwMki0OFMh|ryP NGD2O5BUSU6JRWK=
MDA-MB-134-VI Ml;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\T[GlEPTB;ND6zNFYxOSEQvF2= M1j0fnNCVkeHUh?=
Becker NFi1UJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fpPGlEPTB;ND60O|M{PiEQvF2= MoLjV2FPT0WU
DMS-153 M1\iSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTRwNk[0O|Uh|ryP MWLTRW5ITVJ?
TGBC1TKB MmTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHIO4NKSzVyPUSuOlg2OTVizszN MoLGV2FPT0WU
EW-3 NFvrfllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTRwN{[yOFgh|ryP MWrTRW5ITVJ?
KE-37 M4\sbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTRwOE[xPVYh|ryP Mlq0V2FPT0WU
NCI-H23 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Lhc2lEPTB;ND64O|IzPyEQvF2= M1nnTXNCVkeHUh?=
MC116 NULPd2FQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoW4TWM2OD12Lkm0NVI3KM7:TR?= NXTiOIhjW0GQR1XS
NH-12 M{Xpc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTRwOU[0N|kh|ryP MYPTRW5ITVJ?
CTB-1 NHXPeVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITHb3VKSzVyPUSuPVc4OjFizszN MV3TRW5ITVJ?
KM-H2 NYHS[pBXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknTTWM2OD13LkC1N|I{KM7:TR?= MofmV2FPT0WU
MOLT-4 M{\mcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIi4TIpKSzVyPUWuNVE5OyEQvF2= Ml;oV2FPT0WU
NCI-H2141 MoT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTVwMUSyOlgh|ryP M2q4WXNCVkeHUh?=
EB-3 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\ZdWlEPTB;NT6xO|UxPCEQvF2= MXjTRW5ITVJ?
NCI-H1522 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVK3Z|drUUN3ME21MlI3OzJ{IN88US=> MWnTRW5ITVJ?
MRK-nu-1 MkjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTVwNEO2N|Mh|ryP NFTLe|ZUSU6JRWK=
no-11 MlfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LJVmlEPTB;NT60O|A5PyEQvF2= NF7lZnVUSU6JRWK=
CESS NWexTZVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTVwNUiwN|Qh|ryP MnToV2FPT0WU
KMOE-2 NGLofFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\OTWM2OD13LkW4OlU6KM7:TR?= NGXOOnVUSU6JRWK=
REH NGji[IlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHqyNpZKSzVyPU[uNlU3OThizszN MnWxV2FPT0WU
KU812 NUfIfI45T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLMTWM2OD14LkSyO|kyKM7:TR?= MoS4V2FPT0WU
SK-N-FI MmXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXDTIFlUUN3ME22MlYxPjd2IN88US=> NHLodGtUSU6JRWK=
MMAC-SF MnnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4q2NWlEPTB;Nz6wOlQ6OiEQvF2= NWTBSGhxW0GQR1XS
RCC10RGB NXTlO3QyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\Od3pKSzVyPUeuNlI6PzdizszN MYHTRW5ITVJ?
NCI-H322M MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTVNIhNUUN3ME23MlM{OzN3IN88US=> MYHTRW5ITVJ?
NB6 NGC5XJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTDW5VnUUN3ME23MlU1QDl7IN88US=> NH\YXGZUSU6JRWK=
MN-60 M3jmUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTdwNkmyNVUh|ryP MX7TRW5ITVJ?
NCI-H1092 NHnoS29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jR[mlEPTB;OD6wNVc{PCEQvF2= NYTldGJQW0GQR1XS
EKVX MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRThwNEewOlYh|ryP M3;0fXNCVkeHUh?=
D-263MG NUPkZVd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\GdGpKSzVyPUiuOVU{QTZizszN NWK0b3JHW0GQR1XS
NCI-H209 NIG1fJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vHWWlEPTB;OD62OFAxPiEQvF2= NEmwTI1USU6JRWK=
IST-SL1 M4HWOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rs[mlEPTB;OD64PVg6OiEQvF2= NWi3bpdiW0GQR1XS
ACN MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTlwMUmxOVch|ryP MoOxV2FPT0WU
MHH-PREB-1 NI\P[W5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnPTWM2OD17LkKxNlE6KM7:TR?= Ml7WV2FPT0WU
EW-11 M3nPPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWqwSmI6UUN3ME25MlY2Ozl4IN88US=> MYnTRW5ITVJ?
KASUMI-1 M{L5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTlwN{i3O{DPxE1? NHPsWFZUSU6JRWK=
KINGS-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTFyLkKzOFch|ryP NWjOcG1JW0GQR1XS
EVSA-T M3HjWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXmTWM2OD1zMD6zNVkzKM7:TR?= NYPSRlJnW0GQR1XS
DSH1 M{XGZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojWTWM2OD1zMD6zPVczKM7:TR?= MUTTRW5ITVJ?
COLO-824 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljkTWM2OD1zMD64OlY6KM7:TR?= MoTxV2FPT0WU
K052 NGXrN2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTFyLkmzNlIh|ryP MXrTRW5ITVJ?
SK-MEL-2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTFyLkm5N|kh|ryP NX7zVmxHW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-ALK / ALK / p-STAT3 / STAT3 / p-ERK / ERK / p-AKT / AKT / Survivin / BIM / PARP ; 

PubMed: 22240786     


H3122 or H2228 cells were incubated with the indicated concentrations of TAE684 for 48 h, after which cell lysates were prepared and subjected to immunoblot analysis with antibodies to phosphorylated (p) or total forms of ALK, STAT3, ERK, or AKT as well as with those to BIM, to survivin, to PARP, or to β-actin (loading control). The positions of the bands for EML4–ALK, BIMEL, and intact and cleaved forms of PARP are shown for the corresponding antibodies. 

p-ROS1 / ROS1 ; 

PubMed: 25351743     


Inhibition of phospho-ROS1 by various identified ROS1 inhibitors selected from the high throughput screening. CD74-ROS1-WT-expressing (clone 6) or CD74-ROS1-G2032R-expressing Ba/F3 cells were exposed to increasing concentrations of cabozantinib (XL184), TAE684, or foretinib (B) for 2 h. Following treatment, the cell lysates were immunoblotted to detect the indicated proteins.

22240786 25351743
Growth inhibition assay
Cell viability; 

PubMed: 18594010     


NSCLC cells were treated with TAE-684 at the indicated concentrations, and viable cells were measured after 72 hours of treatment. The percentage of viable cells is shown relative to untreated controls. A549 (KRAS G12S); PC9 (EGFRdelE746_A750); H2228 (EML4-ALK variant 3); H3122 (EML4-ALK variant 1); DFCI032 (EML4-ALK variant 1). 

18594010
体内研究 3和10 mg/kg NVP-TAE684处理4周后,明显减慢淋巴癌生长转移,作用于Karpas-299淋巴癌模型没有毒性。用NVP-TAE684处理Karpas-299 淋巴癌也诱导疾病衰退和下调CD30表达。[1] NVP-TAE684 作用于H3122 CR移植瘤显示出明显的抗癌活性。[2] 用NVP-TAE684处理也提升ALK突变的表现型,尤其是ALKR1275Q, 然而Crizotinib 对表现型没有影响。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

体外酶实验:

使用同质时间分辨荧光法测定NVP-TAE684作用于InsR和IGF1R的IC50 值。ATP (10 mM)和20 mg/ml 生物素PolyEY (Glu, Tyr 4:1),与50 nL NVP-TAE684连续稀释液 (10-500 nM) ,和4 ng InsR 酶,和激酶反应buffer (包括20 mM Tris×HCl, pH 为7.5 /10 mM MgCl2/3 mM MnCl2/1 mM DTT/10 mM NaVO4/0.1 mg/ml of BSA)混合。在室温下温育1小时。加入10 mL检测液终止反应,检测液含50 mM EDTA, 500 mM KF, 0.5 mg/ml of BSA, 5 mg/ml Eu3+ 穴状化合物标记的磷酸酪氨酸抗体PT66-K,及5 mg/ml 链霉亲和素-XLent。反应进行半小时,在Analyst GT上读取荧光信号。
细胞实验:[1]
- 合并
  • Cell lines: 表达Luciferase的Karpas-299, SU-DHL-1,和Ba/F3 细胞,及稳定表达Ba/F3转变的 NPM-ALK, BCR-ABL,或TEL激酶融合构成。
  • Concentrations: 1 nM-10 μM
  • Incubation Time: 2到3天
  • Method: 细胞按每孔2.5×104个接种在384孔板上,和NVP-TAE684的连续稀释液或DMSO温育2到3天。使用Luciferase表达系统测定细胞增殖和存活,然后用Bright-Glo Luciferase 实验系统测评。使用XLFit 软件测定IC50值。
    (Only for Reference)
动物实验:[1]
- 合并
  • Animal Models: 4到6周大的携带Karpas-299移植瘤的雌性Fox Chase SCIDBeige 鼠
  • Dosages: 1, 3, 和 10 mg/kg
  • Administration: 每天口服饲喂,持续3周。
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 3 mg/mL (4.88 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
30% PEG400+0.5% Tween80+5% propylene glycol, pH 4
10 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 614.2
化学式

C30H40ClN7O3S

CAS号 761439-42-3
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项
免费分装抑制剂

ALK Signaling Pathway Map

ALK Inhibitors with Unique Features

相关ALK产品

Tags: 购买TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684)供应商 | 采购TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684)价格 | TAE684 (NVP-TAE684)生产 | 订购TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID